Search

Your search keyword '"Xu, Xinjie"' showing total 264 results
Start Over Author "Xu, Xinjie" Language english
264 results on '"Xu, Xinjie"'

3. Mining the Characteristics of COVID-19 Patients in China: Analysis of Social Media Posts

Author

Huang, Chunmei, Xu, Xinjie, Cai, Yuyang, Ge, Qinmin, Zeng, Guangwang, Li, Xiaopan, Zhang, Weide, Ji, Chen, and Yang, Ling

Subjects
Computer applications to medicine. Medical informatics, R858-859.7, Public aspects of medicine, RA1-1270
Abstract

BackgroundIn December 2019, pneumonia cases of unknown origin were reported in Wuhan City, Hubei Province, China. Identified as the coronavirus disease (COVID-19), the number of cases grew rapidly by human-to-human transmission in Wuhan. Social media, especially Sina Weibo (a major Chinese microblogging social media site), has become an important platform for the public to obtain information and seek help. ObjectiveThis study aims to analyze the characteristics of suspected or laboratory-confirmed COVID-19 patients who asked for help on Sina Weibo. MethodsWe conducted data mining on Sina Weibo and extracted the data of 485 patients who presented with clinical symptoms and imaging descriptions of suspected or laboratory-confirmed cases of COVID-19. In total, 9878 posts seeking help on Sina Weibo from February 3 to 20, 2020 were analyzed. We used a descriptive research methodology to describe the distribution and other epidemiological characteristics of patients with suspected or laboratory-confirmed SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection. The distance between patients’ home and the nearest designated hospital was calculated using the geographic information system ArcGIS. ResultsAll patients included in this study who sought help on Sina Weibo lived in Wuhan, with a median age of 63.0 years (IQR 55.0-71.0). Fever (408/485, 84.12%) was the most common symptom. Ground-glass opacity (237/314, 75.48%) was the most common pattern on chest computed tomography; 39.67% (167/421) of families had suspected and/or laboratory-confirmed family members; 36.58% (154/421) of families had 1 or 2 suspected and/or laboratory-confirmed members; and 70.52% (232/329) of patients needed to rely on their relatives for help. The median time from illness onset to real-time reverse transcription-polymerase chain reaction (RT-PCR) testing was 8 days (IQR 5.0-10.0), and the median time from illness onset to online help was 10 days (IQR 6.0-12.0). Of 481 patients, 32.22% (n=155) lived more than 3 kilometers away from the nearest designated hospital. ConclusionsOur findings show that patients seeking help on Sina Weibo lived in Wuhan and most were elderly. Most patients had fever symptoms, and ground-glass opacities were noted in chest computed tomography. The onset of the disease was characterized by family clustering and most families lived far from the designated hospital. Therefore, we recommend the following: (1) the most stringent centralized medical observation measures should be taken to avoid transmission in family clusters; and (2) social media can help these patients get early attention during Wuhan’s lockdown. These findings can help the government and the health department identify high-risk patients and accelerate emergency responses following public demands for help.

Published
2020
Full Text
View/download PDF

15. Prospective evaluation of genome sequencing to compare conventional cytogenetics in acute myeloid leukemia

Author

Pitel, Beth A., Zepeda-Mendoza, Cinthya, Sachs, Zohar, Tang, Hongwei, Shivaram, Suganti, Sharma, Neeraj, Smadbeck, James B., Smoley, Stephanie A., Pearce, Kathryn E., Luoma, Ivy M., Cook, Joselle, Litzow, Mark R., Hoppman, Nicole L., Viswanatha, David, Xu, Xinjie, Ketterling, Rhett P., Greipp, Patricia T., Peterson, Jess F., and Baughn, Linda B.

Published
2023
Full Text
View/download PDF

24. Disparity in the detection of chromosome 15 centromere in patients of African ancestry with a plasma cell neoplasm

Author

Koleilat, Alaa, Tang, Hongwei, Sharma, Neeraj, Yan, Huihuang, Tian, Shulan, Smadbeck, James, Shivaram, Suganti, Meyer, Reid, Pearce, Kathryn, Baird, Michael, Zepeda-Mendoza, Cinthya J., Xu, Xinjie, Greipp, Patricia T., Peterson, Jess F., Ketterling, Rhett P., Bergsagel, P. Leif, Vachon, Celine, Rajkumar, S. Vincent, Kumar, Shaji, Asmann, Yan W., Elhaik, Eran, and Baughn, Linda B.

Published
2023
Full Text
View/download PDF

26. A community approach to the cancer-variant-interpretation bottleneck

Author

Krysiak, Kilannin, Danos, Arpad M., Kiwala, Susanna, McMichael, Joshua F., Coffman, Adam C., Barnell, Erica K., Sheta, Lana, Saliba, Jason, Grisdale, Cameron J., Kujan, Lynzey, Pema, Shahil, Lever, Jake, Spies, Nicholas C., Chiorean, Andreea, Rieke, Damian T., Clark, Kaitlin A., Jani, Payal, Takahashi, Hideaki, Horak, Peter, Ritter, Deborah I., Zhou, Xin, Ainscough, Benjamin J., Delong, Sean, Lamping, Mario, Marr, Alex R., Li, Brian V., Lin, Wan-Hsin, Terraf, Panieh, Salama, Yasser, Campbell, Katie M., Farncombe, Kirsten M., Ji, Jianling, Zhao, Xiaonan, Xu, Xinjie, Kanagal-Shamanna, Rashmi, Cotto, Kelsy C., Skidmore, Zachary L., Walker, Jason R., Zhang, Jinghui, Milosavljevic, Aleksandar, Patel, Ronak Y., Giles, Rachel H., Kim, Raymond H., Schriml, Lynn M., Mardis, Elaine R., Jones, Steven J. M., Raca, Gordana, Rao, Shruti, Madhavan, Subha, Wagner, Alex H., Griffith, Obi L., and Griffith, Malachi

Published
2022
Full Text
View/download PDF

28. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)

Author

Horak, Peter, Griffith, Malachi, Danos, Arpad M., Pitel, Beth A., Madhavan, Subha, Liu, Xuelu, Chow, Cynthia, Williams, Heather, Carmody, Leigh, Barrow-Laing, Lisa, Rieke, Damian, Kreutzfeldt, Simon, Stenzinger, Albrecht, Tamborero, David, Benary, Manuela, Rajagopal, Padma Sheila, Ida, Cristiane M., Lesmana, Harry, Satgunaseelan, Laveniya, Merker, Jason D., Tolstorukov, Michael Y., Campregher, Paulo Vidal, Warner, Jeremy L., Rao, Shruti, Natesan, Maya, Shen, Haolin, Venstrom, Jeffrey, Roy, Somak, Tao, Kayoko, Kanagal-Shamanna, Rashmi, Xu, Xinjie, Ritter, Deborah I., Pagel, Kym, Krysiak, Kilannin, Dubuc, Adrian, Akkari, Yassmine M., Li, Xuan Shirley, Lee, Jennifer, King, Ian, Raca, Gordana, Wagner, Alex H., Li, Marylin M., Plon, Sharon E., Kulkarni, Shashikant, Griffith, Obi L., Chakravarty, Debyani, and Sonkin, Dmitriy

Published
2022
Full Text
View/download PDF

30. Integrating single‐cell RNA sequencing data to decipher heterogeneity and function of macrophages in various organs and diseases.

Author

Xu, Xinjie, Wu, Zichen, Zeng, Zhiwei, Cao, Jiaying, and Chen, Liang

Subjects
*KUPFFER cells, *ALVEOLAR macrophages, *BONE marrow cells, *MYELOID cells, *INTERSTITIAL cells
Abstract

The article discusses the integration of single-cell RNA sequencing data to understand the heterogeneity and function of macrophages in different organs and diseases. It highlights the developmental origins of macrophages, their classification into M1 and M2 types, and the challenges of binary classification in explaining diverse pathophysiological processes. The use of single-cell RNA sequencing technology has revolutionized the study of macrophages, providing insights into their heterogeneity, functional diversity, lineage origin, differentiation trajectories, and cellular communication networks. The article also emphasizes the importance of validating findings from omics data and the advantages and challenges of integrating single-cell research across various organs and diseases. [Extracted from the article]

Published
2024
Full Text
View/download PDF

45. Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group

Author

Xu, Xinjie, Bryke, Christine, Sukhanova, Madina, Huxley, Emma, Dash, D.P., Dixon-Mciver, Amanda, Fang, Min, Griepp, Patricia T., Hodge, Jennelle C., Iqbal, Anwar, Jeffries, Sally, Kanagal-Shamanna, Rashmi, Quintero-Rivera, Fabiola, Shetty, Shashi, Slovak, Marilyn L., Yenamandra, Ashwini, Lennon, Patrick A., and Raca, Gordana

Published
2018
Full Text
View/download PDF

46. Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms

Author

Kanagal-Shamanna, Rashmi, Hodge, Jennelle C., Tucker, Tracy, Shetty, Shashi, Yenamandra, Ashwini, Dixon-McIver, Amanda, Bryke, Christine, Huxley, Emma, Lennon, Patrick A., Raca, Gordana, Xu, Xinjie, Jeffries, Sally, Quintero-Rivera, Fabiola, Greipp, Patricia T., Slovak, Marilyn L., Iqbal, M. Anwar, and Fang, Min

Published
2018
Full Text
View/download PDF

47. A comprehensive value-based method for new nuclear medical service pricing: with case study of radium [223Ra] bone metastases treatment.

Author

Wang, Haode, Sun, Hui, Fu, Yuyan, Cheng, Wendi, Jin, Chunlin, Shi, Hongcheng, Luo, Yashuang, Xu, Xinjie, and Wang, Haiyin

Subjects
BONE metastasis, PRICES, HEALTH information systems, DRUG prices, MEDICAL economics, RADIUM, ENDOSSEOUS dental implants
Abstract

Importance: Innovative nuclear medicine services offer substantial clinical value to patients. However, these advancements often come with high costs. Traditional payment strategies do not incentivize medical institutes to provide new services nor determine the fair price for payers. A shift towards a value-based pricing strategy is imperative to address these challenges. Such a strategy would reconcile the cost of innovation with incentives, foster transparent allocation of healthcare resources, and expedite the accessibility of essential medical services. Objective: This study aims to develop and present a comprehensive, value-based pricing model for new nuclear medicine services, illustrated explicitly through a case study of the radium [223Ra] treatment for bone metastases. In constructing the pricing model, we have considered three primary value determinants: the cost of the new service, associated service risk, and the difficulty of the service provision. Our research can help healthcare leaders design an evidence-based Fee-For-Service (FFS) payment reference pricing with nuclear medicine services and price adjustments. Design, setting and participants: This multi-center study was conducted from March 2021 to February 2022 (including consultation meetings) and employed both qualitative and quantitative methodologies. We organized focus group consultations with physicians from nuclear medicine departments in Beijing, Chongqing, Guangzhou, and Shanghai to standardize the treatment process for radium [223Ra] bone metastases. We used a specially designed 'Radium Nuclide [223Ra] Bone Metastasis Data Collection Form' to gather nationwide resource consumption data to extract information from local databases. Four interviews with groups of experts were conducted to determine the add-up ratio, based on service risk and difficulty. The study organized consultation meeting with key stakeholders, including policymakers, service providers, clinical researchers, and health economists, to finalize the pricing equation and the pricing result of radium [223Ra] bone metastases service. Main outcomes and measures: We developed and detailed a pricing equation tailored for innovative services in the nuclear medicine department, illustrating its application through a step-by-step guide. A standardized service process was established to ensure consistency and accuracy. Adhering to best practice guidelines for health cost data analysis, we emphasized the importance of cross-validation of data, where validated data demonstrated less variation. However, it required a more advanced health information system to manage and analyze the data inputs effectively. Results: The standardized service of radium [223Ra] bone metastases includes: pre-injection assessment, treatment plan, administration, post-administration monitoring, waste disposal and monitoring. The average duration for each stage is 104 min, 39 min, 25 min, 72 min and 56 min. A standardized monetary value for medical consumables is 54.94 yuan ($7.6), and the standardised monetary value (medical consumables cost plus human input) is 763.68 yuan ($109.9). Applying an agreed value add-up ratio of 1.065, the standardized value is 810.19 yuan ($116.9). Feedback from a consultation meeting with policymakers and health economics researchers indicates a consensus that the pricing equation developed was reasonable and well-grounded. Conclusion: This research is the first study in the field of nuclear medicine department pricing methodology. We introduce a comprehensive value-based nuclear medical service pricing method and use radium[223Ra] bone metastases treatment pricing in China as a case study. This study establishes a novel pricing framework and provides practical instructions on its implementation in a real-world healthcare setting. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis

Author

Pitel, Beth A., Sharma, Neeraj, Zepeda-Mendoza, Cinthya, Smadbeck, James B., Pearce, Kathryn E., Cook, Joselle M., Vasmatzis, George, Sachs, Zohar, Kanagal-Shamanna, Rashmi, Viswanatha, David, Xiao, Sheng, Jenkins, Robert B., Xu, Xinjie, Hoppman, Nicole L., Ketterling, Rhett P., Peterson, Jess F., Greipp, Patricia T., and Baughn, Linda B.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results